Oaktree Capital Management’s ZyVersa Therapeutics ZVSA Stock Holding History

Oaktree Capital Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-571	Closed	-$2M	–	353
2022 Q3	$2M	Hold	571	–	–	0.02%	283
2022 Q2	$1.99M	Hold	571	–	–	0.02%	274
2022 Q1	$1.98M	Buy	+571	New	+$1.98M	0.02%	261

Other funds holding ZVSA

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Oaktree Capital Management's ZVSA Position: Q4 2022 in Review

Oaktree Capital Management sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 571 shares — an estimated $2M sold.

Oaktree Capital Management first reported a position in ZVSA in Q1 2022 and held it in 3 quarters. The position peaked at $2M in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

Oaktree Capital Management reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
Oaktree Capital Management sold 571 ZyVersa Therapeutics shares in Q4 2022, an estimated $2M.
Oaktree Capital Management first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 3 quarters.
Oaktree Capital Management's ZyVersa Therapeutics position peaked at $2M in Q3 2022.
2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on Oaktree Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.